The isCGM Use and Hypoglycemic Episodes and Fear of Hypoglycemia in Newly Diagnosed Type 1 Diabetes (PENELOPE)
The Impact of the isCGM Use on the Hypoglycemic Episodes and Fear of Hypoglycemia in Patients With Newly Diagnosed Type 1 Diabetes
Sponsor: Diabetes Poland
Terminated
The study ended early due to CGM reimbursement policy changes, after that most patients eligible for the study could have isCGM reimbursed.
Other Diabetes Mellitus, Type 1 trials with similar outcome
Listed as NCT06414824, this NA trial focuses on Diabetes Mellitus, Type 1 and remains terminated or withdrawn. Sponsored by Diabetes Poland, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Nov 2024 — Present [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Nov 2024 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jun 2024 — Jul 2024 [monthly]
Recruiting NA
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Diabetes Poland
- Jagiellonian University
For direct contact, visit the study record on ClinicalTrials.gov .